BMS-433771 is a potent orally active inhibitor of respiratory syncytial virus (RSV) . BMS-433771 is active against both A and B groups of RSV , with an average EC 50 of 20 nM. BMS-433771 can be used for the research of respiratory tract disease In Vitro BMS-433771 has inhibitory against both A and B groups of RSV, with an average EC 50 of 20 nM. BMS-433771 can inhibit viral F protein-induced membrane fusion. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo BMS-433771 (p.o.; 1-200 mg/kg; single or bid 4 days) shows prophylactic efficacy via oral dosing，but has considerable pharmacodynamic differences between the two rodent models. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: rodent models of RSV infection(cotton rat and mice) Dosage: 1, 10, and 50 mg/kg (mice); 25, 50, 100, and 200 mg/kg (rat) Administration: oral, single or bid 4 days Result: Had prophylactic efficacy via oral dosing in both animal models. Showed RSV infection more sensitive to inhibition in the BALB/c mouse host than in the cotton rat. Form:Solid IC50& Target:EC50: 20 nM (RSV)